The best modality for targeted protein degradation
Molecular glue degraders eliminate disease-causing proteins by promoting their interaction with the cell’s ubiquitin-proteasome system (UPS).
Specifically, molecular glues have the potential to enhance binding between a disease-causing protein and an E3 ligase enzyme. These small molecules can effectively promote the formation of a complex between two proteins, even when the molecular glue has low binding affinity for either protein partner.
Molecular glues are a powerful tool for directing the UPS and their versatility allows us to effectively degrade undruggable targets.
The most challenging disease-causing targets require a transformational approach. Molecular glues are a new, validated wave of medicines, that render challenging targets druggable.
TRIANA’s target-first and rational approach to molecular glue discovery is unlocking the full potential of small molecules to manipulate key disease drivers for potential therapeutic benefit.
We begin with a disease target, then use our proprietary protein-protein pairing engine to identify protein partners that have the potential to impact the disease target through induced proximity
Our strategy leverages deep mechanistic insight and diverse chemical space to explore entirely new molecular glues.
TRI-611 is an orally administered, first-in-class investigational therapy that is specifically designed to target and degrade ALK fusion proteins, the abnormal proteins that are the underlying cause of tumor growth in patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC).
TRIANA is conducting a global Phase 1/2 clinical trial, investigating TRI-611 for the treatment of adult patients with ALK+ NSCLC.
